469. Analysis of ganciclovir resistant HHV-6Bclinical isolates by using PCR with quenching probes (QP-PCR)
Session: Poster Abstract Session: Prevention and Treatment of Viral Infections
Thursday, October 3, 2013
Room: The Moscone Center: Poster Hall C
Posters
  • yehwz2013IDSA.png (646.6 kB)
  • Background: Human herpesvirus 6 B (HHV-6B) causes exanthem subitum at the time of primary infection. Additionally, its reactivation causes several severe clinical manifestations such as post-transplant acute limbic encephalitis in transplant recipients. It has been demonstrated that ganciclovir (GCV) or foscarnet has antiviral effect against HHV-6B. As new molecular method for screening of GCV resistant HHV-6B has been developed, we sought to elucidate the frequency of GCV resistant HHV-6B in clinical isolates obtaining from the patients with primary viral infection and viral reactivation.Methods: Thirty HHV-6B clinical isolates recovered from the 9 hematopoietic stem cell transplant (HSCT) recipients and 21 HHV-6B clinical isolates recovered from 21 exanthem subitum(ES) patients were used in this study. Although 6 of the 9 HSCT recipients received GCV administration during the observation period, no ES patients was treated by GCV. PCR with quenching probe (QP-PCR) was used for screening of the six SNPs in U69 gene, which are associated with GCV resistant.Results: As we expected, none of the 21 clinical isolates recovered from the ES patients carried the 6 SNPs. Additionally the 6 SNPs were not identified from all 30 clinical isolates recovered from the HSCT recipients even though 6 of the 9 recipients received GCV administration. In order to confirm the result, sequence analysis of U69 gene was carried out in 6 isolates recovered from the recipients with GCV treatment. No mutation was identified in U69 gene in the isolates.Conclusion: This is the first report demonstrating the incidence of GCV resistant HHV-6B in clinical isolates. This study suggests that occurrence of GCV resistant HHV-6B may be rare even though in HSCT recipients with GCV administration. Further study is needed to elucidate an association between dose and duration of GCV administration and emergence of GCV resistant virus.
    Hiroyuki Hiramatsu, MS1, Ryota Suzuki, Ph.D1, Shigeki Yamada, Ph.D1, Masaru Ihira, Ph.D.2, Yoshiki Kawamura, MD3, Erina Matsuoka, MD3, Hiroki Miura, MD3 and Tetsushi Yoshikawa, MD3, (1)Pharmacy, Fujita Health University Hospital, Toyoake, Japan, (2)Faculty of Clinical Engineering, Fujita Health University, Toyoake, Japan, (3)Dept. of Pediatrics, Fujita Health University School of Medicine, Toyoake, Japan

    Disclosures:

    H. Hiramatsu, None

    R. Suzuki, None

    S. Yamada, None

    M. Ihira, None

    Y. Kawamura, None

    E. Matsuoka, None

    H. Miura, None

    T. Yoshikawa, None

    Findings in the abstracts are embargoed until 12:01 a.m. PST, Oct. 2nd with the exception of research findings presented at the IDWeek press conferences.